Scotiabank Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its target price raised by Scotiabank from $177.00 to $200.00 in a report released on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Wells Fargo & Company increased their price target on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Morgan Stanley lifted their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a report on Friday. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $169.19.

Gilead Sciences Price Performance

GILD opened at $170.68 on Friday. The firm’s fifty day moving average is $150.87 and its two-hundred day moving average is $139.79. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $175.65.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The company had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the business earned $2.47 EPS. The firm’s revenue was up 6.8% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences will post -0.48 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GILD. Client 1ST Advisory Group LLC boosted its position in shares of Gilead Sciences by 4.0% in the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 69 shares during the period. Grove Bank & Trust grew its stake in Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after acquiring an additional 74 shares in the last quarter. Financial Connections Group Inc. increased its holdings in Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares during the period. Wilkerson Advisory Group LLC increased its holdings in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the period. Finally, HBW Advisory Services LLC increased its holdings in Gilead Sciences by 2.4% during the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 79 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.